Previous Article | Next Article ![]()
Antimicrobial Agents and Chemotherapy, May 1998, p. 1015-1021, Vol. 42, No. 5
Department of Microbiology,
Received 28 July 1997/Returned for modification 15 December
1997/Accepted 15 February 1998
The supernatants taken from Pseudomonas aeruginosa and
Escherichia coli cultures in human sera or chemically
defined M9 medium in the presence of ceftazidime (CAZ) contained high
levels of endotoxin, while those taken from the same cultures in the
presence of imipenem (IPM) yielded a very low level of endotoxin. The
biological activities of endotoxin in the supernatants were compared
with those of phenol water-extracted lipopolysaccharide (LPS). The endotoxin released from the organisms as a result of CAZ treatment (CAZ-released endotoxin) contained a large amount of protein. The
protein, however, lacked endotoxic activity, since the endotoxin did
not show any in vivo toxic effects in LPS-hyporesponsive C3H/HeJ mice
sensitized with D-(+)-galactosamine (GalN) or any
activation of C3H/HeJ mouse macrophages in vitro. The activities of
CAZ- and IPM-released endotoxin (as assessed by a chromogenic
Limulus test) were fundamentally the same as those of
P. aeruginosa LPS, since their regression lines were
parallel. The CAZ-released endotoxin was similar to purified LPS with
respect to the following biological activities in LPS-responsive
C3H/HeN mice and LPS-hyporesponsive C3H/HeJ mice: lethal toxicity in
GalN-sensitized mice, in vitro induction of tumor necrosis factor- and
NO production by macrophages, and mitogen-activated protein kinase
activation in macrophages. The macrophage activation by CAZ-released
endotoxin as well as LPS was mainly dependent on the presence of serum
factor and CD14 antigen. Polymyxin B blocked the activity. These
findings indicate that the endotoxic activity of CAZ-released endotoxin
is due primarily to LPS (lipid A).
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Biological Characterization of Endotoxins Released
from Antibiotic-Treated Pseudomonas aeruginosa and
Escherichia coli
*
Corresponding author. Mailing address: Department of
Microbiology, Jichi Medical School, Minamikawachi-machi, Tochigi-ken 329-0498, Japan. Phone: 81-285-44-2111, ext. 3160. Fax: 81-285-44-1175. E-mail: tkirikae{at}jichi.ac.jp.
Antimicrobial Agents and Chemotherapy, May 1998, p. 1015-1021, Vol. 42, No. 5
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
| Clin. Vaccine Immunol. | Clin. Microbiol. Rev. |
|---|---|
| J. Clin. Microbiol. | ALL ASM JOURNALS |